Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2DG (high affinity) and CYP3A4 (low affinity): Implications for interactions with enzyme-inducing drugs

The human cytochrome P450 (CYP) isoforms mediating nortriptyline 10-hydroxylatian have been identified using kinetic studies on heterologously expressed human CYPs and chemical inhibition studies on human liver microsomes. Nortriptyline was metabolized to E-10-hydroxynortriptyline by human lymphoblast-expressed CYPs 2D6 (K-m 2.1 mu M) and 3A4 (K-m 37.4 mu M) with high and low affinity respectively, whereas CYPs 1A2, 2A6, 2B6, 2C9, 2C19, and 2E1 had no detectable activity. Human liver microsomal nortriptyline E-10-hydroxylation displayed biphasic kinetics. The high-affinity component (K-m 1.3 +/- 0.4 mu M, n = 11 livers) was selectively inhibited by the CYP2D6 inhibitor quinidine, whereas the CYP3A4 inhibitor ketoconazole selectively inhibited the low-affinity component (K-m 24.4 +/- 7 mu M, n = 11 livers), inhibition by ketoconazole increased with increasing substrate concentration, whereas the reverse was true for quinidine. The V-max of the low-affinity component in human liver microsomes was significantly correlated (r(2) = 0.84) with the relative activity factor for CYP3A4, a measure of the amount of catalytically active enzyme. A simulation of the relative contribution of CYPs 2D6 and 3A4 to net nortriptyline hydroxylation rate suggested that the relative contribution of CYP3A4 is only 20% even at the higher end of the therapeutic range. Induction of CYP3A4 will increase its importance and increase the net metabolic rate, whereas inhibition of CYP3A4 will be of little importance due to its minimal relative contribution under uninduced conditions. The identification of CYP3A4 as a low-affinity nortriptyline E-10-hydroxylase explains the ability of poor metabolizers of debrisoquin to hydroxylate nortriptyline, as well as the increased in vivo clearance via this pathway caused by CYP3A4-inducing drugs such as pentobarbital, carbamazepine, and rifampin. (C) 1999 the American College of Clinical Pharmacology.